Moleculin Biotech Files 2024 10-K Amendment

Ticker: MBRX · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1659617

Sentiment: neutral

Topics: amendment, annual-report, biotech

TL;DR

Moleculin Biotech filed its 2024 10-K amendment on 4/30/25. Check it for updated financials.

AI Summary

Moleculin Biotech, Inc. filed an amendment (Amendment No. 2) to its annual report on Form 10-K for the fiscal year ended December 31, 2024. The filing was made on April 30, 2025, and pertains to the company's operations and financial status. Moleculin Biotech, Inc. is a pharmaceutical preparations company based in Houston, Texas.

Why It Matters

This filing provides updated information on Moleculin Biotech's financial performance and business operations for the fiscal year 2024, which is crucial for investors to assess the company's current standing.

Risk Assessment

Risk Level: medium — As a biotech company, Moleculin Biotech is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What specific information is being amended in this 10-K filing?

The filing is an amendment (Amendment No. 2) to the Form 10-K for the fiscal year ended December 31, 2024, but the specific details of the amendments are not provided in this header information.

When was the original 10-K filed, or when was this amendment filed?

This amendment (Amendment No. 2) was filed on April 30, 2025.

What is Moleculin Biotech, Inc.'s primary business sector?

Moleculin Biotech, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.

Where is Moleculin Biotech, Inc. headquartered?

The company is headquartered in Houston, Texas, at 5300 Memorial Drive, Suite 950.

What is the SEC file number for Moleculin Biotech, Inc.?

The SEC file number is 001-37758.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Moleculin Biotech, Inc. (MBRX).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing